CatalYm Appoints Christian S. Schade as Chairman of the Board of Directors
Aprea Therapeutics, Inc. (APRE)
Company Research
Source: Business Wire
MUNICH & SAN FRANCISCO--(BUSINESS WIRE)--CatalYm today announced the appointment of seasoned biotech executive Christian S. Schade as Chairman of the Board of Directors. With over 30 years of executive leadership experience across private and public biopharma companies, Mr. Schade will provide board leadership at a crucial stage for the company, following the initiation of four late-stage clinical studies of its lead candidate, the GDF-15 inhibitor visugromab.“With recent positive clinical data, multiple ongoing clinical studies, and a strong leadership team with deep biotechnology and drug development expertise, CatalYm is well positioned for continued clinical and corporate success,” said Christian S. Schade, Chairman of the Board at CatalYm. “The company’s differentiated approach, targeting GDF-15 to address both checkpoint-refractory tumors and cancer cachexia, has shown encouraging anti-tumor activity in multiple solid tumor indications. I look forward to working with the Boa
Show less
Read more
Impact Snapshot
Event Time:
APRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
APRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
APRE alerts
High impacting Aprea Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
APRE
News
- Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual MeetingGlobeNewswire
- Frazier Life Sciences Appoints Christian Schade as Senior AdvisorBusiness Wire
- Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private PlacementGlobeNewswire
- Aprea Therapeutics (APRE) had its "outperform" rating reaffirmed by Wedbush. They now have a $7.00 price target on the stock.MarketBeat
- Aprea Therapeutics (APRE) had its price target lowered by HC Wainwright from $4.00 to $1.20. They now have a "buy" rating on the stock.MarketBeat
APRE
Sec Filings
- 4/29/26 - Form 424B3
- 4/27/26 - Form SCHEDULE
- 4/22/26 - Form S-3
- APRE's page on the SEC website